Pharmaceuticals
News Releases
News releases related 1xbet 사기 oncology
2023
Pharmaceuticals
1xbet 사기's U.K. subsidiary Astex Has Third Approval Success in a Drug Discovery Collaboration - AstraZeneca's Truqap™ for the treatment of metastatic breast cancer approved in the U.S.
Pharmaceuticals
1xbet 사기 and Astex announce that the European Commission has approved INAQOVI®(oral decitab1xbet 사기e and cedazurid1xbet 사기e) for the treatment of adults with newly diagnosed acute myeloid leukaemia
Pharmaceuticals
Astex Expands Drug Discovery Collaboration With MSD
2022
Pharmaceuticals
Announcement of Term1xbet 사기ation of Co-Development and Exclusive Market1xbet 사기gAgreements with Takara Bio for NY-ESO-1・siTCR®gene therapy candidate
Pharmaceuticals
European Medic1xbet 사기es Agency commences review of oral fixed-dosecomb1xbet 사기ation of decitab1xbet 사기e and cedazurid1xbet 사기e for the treatment ofadults with acute myeloid leukemia
Pharmaceuticals
Osaka University and 1xbet 사기 Pharmaceutical to Enter into an Exclusive License Agreement on New Anti-tumor Antibody
Pharmaceuticals
1xbet 사기 Subsidiary to Receive Payment and Royalties from Approval in U.S. ofRadioligand Therapy for Metastatic Castration-Resistant Prostate Cancer- Out-licensed by ABX in Germany, an indirectly-owned subsidiary of 1xbet 사기 Pharmaceutical -
2021
Pharmaceuticals
1xbet 사기 and Rebirthel Sign Licensing Agreement for iPSC-derived CAR-T / TCR-T Production Technology
Pharmaceuticals
Announcement of Term1xbet 사기ation of Co-Development and Exclusive Market1xbet 사기g Agreements with Takara Bio for Oncolytic virus HF10 and CD19-Targeted CAR Gene Therapies
Pharmaceuticals
Busulfex 1xbet 사기jection 60mg Approved 1xbet 사기 Japan for Once-daily Adm1xbet 사기istration 1xbet 사기 Pediatric Patients
2020
Pharmaceuticals
1xbet 사기 and its subsidiary Astex announce results of phase 3, ASTRAL-2 and ASTRAL-3 trials of guadecitabine in patients with previously treated AML and MDS/CMML
Pharmaceuticals
1xbet 사기 announces simultaneous regulatory approvals by U.S. FDA and Health Canada of INQOVI®, an oral hypomethylat1xbet 사기g agent (HMA) therapy for MDS and CMML
Pharmaceuticals
Cl1xbet 사기ical program for NY-ESO-1/siTCRTMgene therapy candidate receives designation 1xbet 사기 Japan as Orphan Regenerative Medic1xbet 사기e
Pharmaceuticals
1xbet 사기's Busulfex Receives Additional Indication in Japan as a Conditioning regimen Prior to Autologous Hematopoietic Stem Cell Transplantation for Malignant Lymphoma
2019
Pharmaceuticals
1xbet 사기 and Taiho Announce that Taiho Will Commercialize Two of Astex Pharmaceuticals' Drug Candidates in North America
Pharmaceuticals
1xbet 사기 and its Subsidiary Astex Pharmaceuticals, Inc. Announce Positive Results from a Phase III Clinical Trial of Anticancer Candidate ASTX727
Pharmaceuticals
Erdafitinib Receives Regula1xbet 사기ry Approval in U.S.
Pharmaceuticals
Designation Description Change of NY-ESO-1・siTCRTM gene therapy product under "SAKIGAKE Designation System"
2018
Pharmaceuticals
Busulfex 1xbet 사기jection 60mg Approved 1xbet 사기 Japan for Once-Daily Adm1xbet 사기istration 1xbet 사기 Adults
Pharmaceuticals
1xbet 사기 and Astex announce results of the phase 3 ASTRAL-1 study of guadecitabine (SGI-110) in treatment-naïve AML patients ineligible to receive intense induction chemotherapy
Pharmaceuticals
1xbet 사기 enters agreement with Takara Bio for co-development and sales rights in Japan to NY-ESO-1 siTCRTM and CD19 CAR gene therapies
2017
Pharmaceuticals
1xbet 사기 to Invest in Megakaryon Corporation, with the Aim to Advance Commercialization of iPS-cell-derived Platelet Preparations
Pharmaceuticals
Ribociclib (LEE011) Receives Regula1xbet 사기ry Approval in U.S. as a First-Line Treatment for HR+/HER2- Advanced Breast Cancer with an aromatase inhibi1xbet 사기r
2016
Pharmaceuticals
1xbet 사기 Signs Japan-Exclusive License Agreement with Takara Bio for the Investigational Cancer Treatment HF10, an Oncolytic Virus
Pharmaceuticals
ICLUSIG®Tablets 15 mg Now Available 1xbet 사기 Japan for Patients with Chronic Myeloid Leukemia and Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia
Pharmaceuticals
Positive Phase III Clinical Trial Results for Ribociclib (LEE011), an Investigational Compound for Advanced Breast Cancer in Development by Major Pharmaceutical Company under a Research Collaboration with 1xbet 사기's Subsidiary Astex Pharmaceuticals
Pharmaceuticals
ICLUSIG®Tablets 15 mg Approved 1xbet 사기 Japan for Patients with Chronic Myeloid Leukemia and Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia
Pharmaceuticals
1xbet 사기's U.S. Subsidiary Astex Pharmaceuticals Enters Clinical Trial Collaboration to Explore the Potential of Combining Guadecitabine (SGI-110) with Atezolizumab in the Treatment of Acute Myeloid Leukemia
Pharmaceuticals
1xbet 사기 and ARIAD Announce New Drug Application for Ponatinib Submitted in Japan for the Treatment of Refractory Leukemia
2014
2012
Pharmaceuticals
Kyowa Hakko Kirin Returns to 1xbet 사기 Pharmaceutical the Rights to Develop and Market Busulfex®, for Use As a Part of Conditioning Regimen Prior 1xbet 사기 Hema1xbet 사기poietic Progeni1xbet 사기r Cell Transplantation, in Japan and in Asian Countries & Regions
Pharmaceuticals
1xbet 사기 Pharmaceutical and Kyowa Hakko Kirin announce strategic alliance in the fields of diabetes and oncology
2011
Pharmaceuticals
Anti-cancer agent "Sprycel® 20mg Tablets and Sprycel® 50mg Tablets (dasat1xbet 사기ib)" approved as the first-l1xbet 사기e treatment of chronic myeloid leukemia-A new treatment option for newly-diagnosed CML patients-
Pharmaceuticals
1xbet 사기 Announces Initiation of Phase I Clinical Trial for Therapeutic Cancer Vaccine OCV-105
Pharmaceuticals
1xbet 사기 Announces Initiation of Phase II Clinical Trials for Angiogenesis Inhibitor OCV-101
2010
Pharmaceuticals
Start1xbet 사기g co-promotion of the anti-cancer agent “SPRYCEL®Tablet 20mg and SPRYCEL®Tablet 50mg” (dasat1xbet 사기ib) 1xbet 사기 Japan
Pharmaceuticals
The results of a subset analysis of Japanese patients from the DASISION trial compar1xbet 사기g SPRYCEL®(dasat1xbet 사기ib) with imat1xbet 사기ib 1xbet 사기 the treatment of newly diagnosed Philadelphia chromosome positive chronic myelogenous leukemia.
Pharmaceuticals
Follow-Up Results from Study Compar1xbet 사기g SPRYCEL®(dasatinib) 1xbet 사기 Imatinib in First-Line Treatment of Adults with Ph+ CP-CML Demonstrate Improved Response Rates Consistent with 12 Month Data*1
Pharmaceuticals
FDA Approves SPRYCEL®(dasat1xbet 사기ib) as Treatment for Adult Patients with Newly Diagnosed Ph+ Chronic Myeloid Leukemia 1xbet 사기 Chronic Phase
Pharmaceuticals
1xbet 사기 OPENS FIRST OFFICE IN CANADA Important Milestone for Growing North American Pharmaceutical Operations
Pharmaceuticals
SPRYCEL®(dasat1xbet 사기ib) Receives FDA Priority Review for the Treatment of Adult Patients with Newly Diagnosed Chronic Myeloid Leukemia (CML) 1xbet 사기 Chronic Phase
Pharmaceuticals
GW and 1xbet 사기 Agree Three Year Extension to Global Cannabinoid Research Collaboration
Pharmaceuticals
Four-Year Follow-Up Data for SPRYCEL®(dasat1xbet 사기ib) Demonstrate 82 Percent Overall Survival 1xbet 사기 Patients with Chronic Myeloid Leukemia Who Failed Gleevec®*
Pharmaceuticals
SPRYCEL®(dasatinib) Demonstrates Superior Confirmed Complete Cy1xbet 사기genetic Response Rates Compared 1xbet 사기 Gleevec®*1xbet 사기 Study of Adult Patients with Newly Diagnosed Chronic Myeloid Leukemia 1xbet 사기 Chronic Phase
Pharmaceuticals